ACI-7104 is under clinical development by AC Immune and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ACI-7104’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ACI-7104 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ACI-7104 overview

PD-01 (PD-01A) is under development for the treatment of Parkinson's disease (PD) and dementia with Lewy bodies. It is administered by subcutaneous route. It is a peptide carrier conjugate vaccine. The vaccine candidate targets the harmful alpha-synuclein protein and is developed based on Affitome technology.

It was under development for the treatment of multiple system atrophy.

AC Immune overview

AC Immune is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate, crenezumab, is a monoclonal antibody that targets abeta in cognitive healthy individuals who are at risk of developing familial Alzheimer’s Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.

Quick View ACI-7104 LOA Data

Report Segments
  • Innovator
Drug Name
  • ACI-7104
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: AC Immune
  • Originator: AFFiRiS
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.